Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.90 Analyst target: $7.00 Upside: 676.66%
IN8bio, Inc., a clinical-stage biotechnology company, is focused on developing new therapies for the treatment of cancers, including solid tumors using genetically modified, autologous, allogeneic gamma-delta T cells. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.